Radnor Capital Management LLC Acquires Shares of 12,798 Stryker Co. (NYSE:SYK)

Radnor Capital Management LLC bought a new stake in Stryker Co. (NYSE:SYK - Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 12,798 shares of the medical technology company's stock, valued at approximately $4,623,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Vanguard Group Inc. increased its holdings in shares of Stryker by 1.0% in the 1st quarter. Vanguard Group Inc. now owns 31,459,393 shares of the medical technology company's stock valued at $11,258,373,000 after purchasing an additional 309,592 shares during the period. JPMorgan Chase & Co. lifted its position in Stryker by 10.4% in the 1st quarter. JPMorgan Chase & Co. now owns 8,651,403 shares of the medical technology company's stock worth $3,096,078,000 after buying an additional 813,311 shares in the last quarter. Clearbridge Investments LLC boosted its stake in shares of Stryker by 2.9% during the 2nd quarter. Clearbridge Investments LLC now owns 2,323,452 shares of the medical technology company's stock valued at $790,554,000 after buying an additional 66,482 shares during the period. TD Asset Management Inc grew its holdings in shares of Stryker by 2.9% during the 1st quarter. TD Asset Management Inc now owns 1,601,380 shares of the medical technology company's stock valued at $573,086,000 after acquiring an additional 44,765 shares in the last quarter. Finally, The Manufacturers Life Insurance Company raised its holdings in shares of Stryker by 4.0% during the second quarter. The Manufacturers Life Insurance Company now owns 1,209,769 shares of the medical technology company's stock worth $411,624,000 after acquiring an additional 46,375 shares in the last quarter. Hedge funds and other institutional investors own 77.09% of the company's stock.

Stryker Stock Performance

Shares of SYK traded down $0.84 on Wednesday, reaching $369.02. 1,366,181 shares of the stock traded hands, compared to its average volume of 1,257,379. The stock's 50-day moving average price is $360.66 and its 200-day moving average price is $344.95. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.91 and a quick ratio of 1.22. The firm has a market cap of $140.68 billion, a price-to-earnings ratio of 39.64, a P/E/G ratio of 2.77 and a beta of 0.91. Stryker Co. has a 12 month low of $266.93 and a 12 month high of $376.04.

Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings data on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.77 by $0.10. Stryker had a net margin of 16.34% and a return on equity of 23.07%. The company had revenue of $5.49 billion during the quarter, compared to analysts' expectations of $5.37 billion. During the same quarter in the prior year, the company posted $2.46 EPS. The business's revenue was up 11.9% on a year-over-year basis. Equities analysts forecast that Stryker Co. will post 12.06 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on SYK. Royal Bank of Canada lifted their price target on Stryker from $386.00 to $400.00 and gave the company an "outperform" rating in a report on Wednesday, October 30th. Stifel Nicolaus dropped their price target on shares of Stryker from $375.00 to $365.00 and set a "buy" rating on the stock in a research note on Wednesday, July 31st. StockNews.com raised shares of Stryker from a "hold" rating to a "buy" rating in a research note on Tuesday, October 1st. Barclays raised their target price on Stryker from $402.00 to $418.00 and gave the company an "overweight" rating in a report on Thursday, October 31st. Finally, Canaccord Genuity Group increased their price objective on Stryker from $360.00 to $400.00 and gave the company a "buy" rating in a report on Wednesday, October 30th. Four research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $393.65.

Insiders Place Their Bets

In other news, insider Viju Menon sold 600 shares of the stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $355.00, for a total value of $213,000.00. Following the completion of the transaction, the insider now directly owns 9,069 shares of the company's stock, valued at approximately $3,219,495. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, insider Viju Menon sold 600 shares of Stryker stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $355.00, for a total transaction of $213,000.00. Following the completion of the transaction, the insider now directly owns 9,069 shares of the company's stock, valued at $3,219,495. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP M Kathryn Fink sold 2,121 shares of the company's stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $370.00, for a total transaction of $784,770.00. Following the sale, the vice president now directly owns 10,042 shares in the company, valued at $3,715,540. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 10,068 shares of company stock worth $3,693,972 over the last quarter. Company insiders own 5.50% of the company's stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.